NovAP
Pipeline
NovAP
Program Target
Acute Pancreatitis
Patient Numbers
2.7 Million
Development Stage
Pre-clinical
NovMetaHealth develops NovAP, a new substance-based best-in-class acute pancreatitis treatment new drug.
NovAP improves mitochondrial dysfunction, endoplasmic reticulum stress, and autophagy, which are the underlying causes of acute pancreatitis by inhibiting mitochondrial calcium channel (VDAC) protein transcription. Different from other products that control calcium channel in cell membranes, NovAP works specifically on mitochondrial calcium channels to minimize the effect on the calcium concentration of the entire cell.
NovMetaHealth identified NovLC’s superior efficacy (compared to existing medications) in animal testing and proved that it can reversibly inhibit pancreatic enzyme secretion and restore digestive enzyme secretion even after stopping the medication. NovMetaHealth, which has proven the treatment effect of NovAP for acute pancreatitis, is striving for continuous R&D.
